Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04883437
Title Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Emory University

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

follicular lymphoma


Acalabrutinib + Obinutuzumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.